Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01353248 · ClinicalTrials.gov registry record · Phase 2
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
NCT01353248 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 141 participants.
The verdict
NCT01353248, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
Study Summary
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.
Interventions
- DRUG GS-5885
- DRUG GS-9451
- DRUG ribavirin tablet
- DRUG Tegobuvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01353248
The ClinicalTrials.gov registry entry for NCT01353248 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which GS-5885 is the first listed.
NCT01353248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01353248 about?
NCT01353248 is a clinical study titled "GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection". The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.
What is the current status of trial NCT01353248?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2011-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01353248?
The interventions under investigation include: GS-5885 (DRUG), GS-9451 (DRUG), ribavirin tablet (DRUG), Tegobuvir (DRUG).
Who is sponsoring clinical trial NCT01353248?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.